The University of Pennsylvania Clinical Oncology Research Cancer Development Program is designed to prepare the next generation of advanced translational cancer researchers, with a particular focus on the development and evaluation of Cellular and Molecular Biologics. This program is built upon several major strengths of the University of Pennsylvania specifically relevant to the goals of this program, including the Abramson Cancer Center at the University of Pennsylvania, as well as the Stokes Research Institute at the Children's Hospital of Philadelphia, the Institute for Clinical Epidemiology and Biostatistics, and the Wistar Institute. In aggregate, these various institutions provide an exceptionally rich training environment that is populated with highly experienced mentors, and all the supporting infrastructure and facilities required to produce world class clinical investigators. That our program is successful is supported by the fact that over 85% of the trainees go on to full-time translational research academic careers. The current competitive renewal application seeks to continue and amplify these training efforts in a program that combines didactic, laboratory and clinical research training. We propose that six trainees be selected from among the pool of clinical oncology trainees currently supported on institutional T32 awards, plus external candidates solicited by advertisement, on the basis of their demonstrated commitment and promise for translational research. These individuals will design a program of """"""""bench-to-bedside"""""""" development of a novel translational protocol under the mentorship of a senior basic investigator and an experienced clinical researcher. The trainees will be supported by this K12 mechanism through both the bench research and clinical trial stages of this research, during which time they will also pursue a sophisticated educational curriculum, including didactic coursework and research seminars targeted at translational clinical research. Progress of the trainees will be closely monitored by individualized Translational Research Committees, and by the program Advisory Committee.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Physician Scientist Award (Program) (PSA) (K12)
Project #
5K12CA076931-15
Application #
8292183
Study Section
Subcommittee G - Education (NCI)
Program Officer
Damico, Mark W
Project Start
1997-09-30
Project End
2014-06-30
Budget Start
2012-07-01
Budget End
2014-06-30
Support Year
15
Fiscal Year
2012
Total Cost
$769,201
Indirect Cost
$31,260
Name
University of Pennsylvania
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Garfall, Alfred L; Stadtmauer, Edward A; Hwang, Wei-Ting et al. (2018) Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight 3:
Bagley, Stephen J; Hwang, Wei-Ting; Brem, Steven et al. (2018) RNA-seq for identification of therapeutically targetable determinants of immune activation in human glioblastoma. J Neurooncol :
Aiello, Nicole M; Maddipati, Ravikanth; Norgard, Robert J et al. (2018) EMT Subtype Influences Epithelial Plasticity and Mode of Cell Migration. Dev Cell 45:681-695.e4
Stitzlein, Russell N; Wojcik, John; Sebro, Ronnie A et al. (2017) Team Approach: Osteosarcoma of the Distal Part of the Femur in Adolescents. JBJS Rev 5:e5
Sander Effron, Samuel; Makvandi, Mehran; Lin, Lilie et al. (2017) PARP-1 Expression Quantified by [18F]FluorThanatrace: A Biomarker of Response to PARP Inhibition Adjuvant to Radiation Therapy. Cancer Biother Radiopharm 32:9-15
Miller, Tamara P; Li, Yimei; Kavcic, Marko et al. (2017) Center-level variation in accuracy of adverse event reporting in a clinical trial for pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Haematologica 102:e340-e343
Tasian, Sarah K; Teachey, David T; Li, Yong et al. (2017) Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia. Blood 129:177-187
Green, Abby M; Budagyan, Konstantin; Hayer, Katharina E et al. (2017) Cytosine Deaminase APOBEC3A Sensitizes Leukemia Cells to Inhibition of the DNA Replication Checkpoint. Cancer Res 77:4579-4588
Wojcik, John; Cooper, Kumarasen (2017) Epigenetic Alterations in Bone and Soft Tissue Tumors. Adv Anat Pathol 24:362-371
George, Erin; Kim, Hyoung; Krepler, Clemens et al. (2017) A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers. JCI Insight 2:e89760

Showing the most recent 10 out of 72 publications